The Africa Centers for Disease Control and Prevention (Africa CDC) has welcomed the first malaria treatment introduced by Novartis and the Medicines for Malaria Venture (MMV) for newborns and infants under five kilogram’s babies.
The Africa CDC in a statement seen by APA on Thursday said the new treatment will close a critical gap in care for Africa’s infants, stating it as a vital step in protecting the most vulnerable.
Eight member states namely Burkina Faso, Côte d’Ivoire, Kenya, Malawi, Mozambique, Nigeria, Tanzania, and Uganda have played a pivotal role in clinical trials and introduction of the treatment, the Africa CDC said.
Until now, infants under five kilogram had no approved treatment and were given unsafe adaptations of medicines for older children. This new formulation, dissolvable in breast milk and with a sweet flavour, provides a safe, effective and infant-friendly option.
Ending malaria could save countless lives and unlock an estimated $126 billion in Africa’s GDP — a transformative impact on both health and prosperity, according to the statement.
The new drug is a shining milestone on the journey to end malaria. It brings hope and tangible progress by delivering life-saving medicine, carefully designed for the youngest and most vulnerable — children under one year and as small as 5 kg.
The future of malaria treatment in Africa is brighter than ever. This approval not only saves lives and secures a better future for Africa’s children; it also reinforces the tremendous potential of the continent, WHO said in a recent statement.
MG/as/APA